Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
= .024) and exceeded cell killing by the PI3K-δ-specific inhibitor idelalisib. Administration of duvelisib to mice engrafted with a PTCL patient-derived xenograft resulted in a shift among tumor-associated macrophages from the immunosuppressive M2-like phenotype to the inflammatory M1-like phenotype. In summary, duvelisib demonstrated promising clinical activity and an acceptable safety profile in relapsed/refractory TCL, as well as preclinical evidence of both tumor cell-autonomous and immune-mediated effects. This trial was registered at www.clinicaltrials.gov as #NCT01476657.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“correlating with a repolarization of the TAM compartment toward immunostimulation (Horwitz et al., 2018)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Horwitz et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S., Stein, H., & Jaffe, E. S. (2011) · Blood · doi:10.1182/blood-2011-01-293050 · Cited by 2,008
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Self-citationPro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Self-citationGrowth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681
Olsen, E. A., Whittaker, S., Kim, Y. H., Duvic, M., Prince, H. M., Lessin, S. R., Wood, G. S., Willemze, R., Demierre, M.-F., Pimpinelli, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0630 · Cited by 666
Self-citationWhittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664
O'Connor, O. A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Jo Lechowicz, M., Savage, K. J., Shustov, A. R., Gisselbrecht, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.9024 · Cited by 647
Self-citationPrince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31266-7 · Cited by 588
Self-citationO'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2782 · Cited by 555
Self-citationIqbal, J., Wright, G., Wang, C., Rosenwald, A., Gascoyne, R. D., Weisenburger, D. D., Greiner, T. C., Smith, L., Guo, S., Wilcox, R. A., et al. (2014) · Blood · doi:10.1182/blood-2013-11-536359 · Cited by 552
Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486
Clayton, E., Bardi, G., Bell, S. E., Chantry, D., Downes, C. P., Gray, A., Humphries, L. A., Rawlings, D., Reynolds, H., Vigorito, E., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020805 · Cited by 446
Mak, V., Hamm, J., Chhanabhai, M., Shenkier, T., Klasa, R., Sehn, L. H., Villa, D., Gascoyne, R. D., Connors, J. M., & Savage, K. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7524 · Cited by 437
Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378
Foss, F. M., Zinzani, P. L., Vose, J. M., Gascoyne, R. D., Rosen, S. T., & Tobinai, K. (2011) · Blood · doi:10.1182/blood-2010-05-231548 · Cited by 353
Self-citationExamining the utility of patient-derived xenograft mouse models
Aparicio, S., Hidalgo, M., & Kung, A. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3944 · Cited by 345
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.008 · Cited by 295
Self-citationLampson, B. L., Kasar, S. N., Matos, T. R., Morgan, E. A., Rassenti, L., Davids, M. S., Fisher, D. C., Freedman, A. S., Jacobson, C. A., Armand, P., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707133 · Cited by 285
Winkler, D. G., Faia, K. L., DiNitto, J. P., Ali, J. A., White, K. F., Brophy, E. E., Pink, M. M., Proctor, J. L., Lussier, J., Martin, C. M., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.017 · Cited by 260
Flinn, I. W., O’Brien, S., Kahl, B., Patel, M., Oki, Y., Foss, F. F., Porcu, P., Jones, J., Burger, J. A., Jain, N., et al. (2018) · Blood · doi:10.1182/blood-2017-05-786566 · Cited by 252
Self-citationPrince, H. M., Duvic, M., Martin, A., Sterry, W., Assaf, C., Sun, Y., Straus, D., Acosta, M., & Negro-Vilar, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2386 · Cited by 233
Reif, K., Okkenhaug, K., Sasaki, T., Penninger, J. M., Vanhaesebroeck, B., & Cyster, J. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2236 · Cited by 230
Coiffier, B., Pro, B., Prince, H. M., Foss, F., Sokol, L., Greenwood, M., Caballero, D., Morschhauser, F., Wilhelm, M., Pinter-Brown, L., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-11 · Cited by 212
Self-citationBalakrishnan, K., Peluso, M., Fu, M., Rosin, N. Y., Burger, J. A., Wierda, W. G., Keating, M. J., Faia, K., O'Brien, S., Kutok, J. L., et al. (2015) · Leukemia · doi:10.1038/leu.2015.105 · Cited by 166
How I treat the peripheral T-cell lymphomas
Moskowitz, A. J., Lunning, M. A., & Horwitz, S. M. (2014) · Blood · doi:10.1182/blood-2013-12-516245 · Cited by 164
Self-citationIdelalisib-associated Colitis: Histologic Findings in 14 Patients
Weidner, A.-S., Panarelli, N. C., Geyer, J. T., Bhavsar, E. B., Furman, R. R., Leonard, J. P., Jessurun, J., & Yantiss, R. K. (2015) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000522 · Cited by 160
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
Weigert, O., Lane, A. A., Bird, L., Kopp, N., Chapuy, B., van Bodegom, D., Toms, A. V., Marubayashi, S., Christie, A. L., McKeown, M., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111694 · Cited by 159
Self-citationIdelalisib-associated Enterocolitis
Louie, C. Y., DiMaio, M. A., Matsukuma, K. E., Coutre, S. E., Berry, G. J., & Longacre, T. A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000525 · Cited by 136
Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function
Fung‐Leung, W. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.002 · Cited by 112
Abelin, J. G., Patel, J., Lu, X., Feeney, C. M., Fagbami, L., Creech, A. L., Hu, R., Lam, D., Davison, D., Pino, L., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058354 · Cited by 87
Self-citationThe future of autologous stem cell transplantation in myeloma
van Rhee, F., Giralt, S., & Barlogie, B. (2014) · Blood · doi:10.1182/blood-2014-03-561985 · Cited by 53
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Jacobson, C., Kopp, N., Layer, J. V., Redd, R. A., Tschuri, S., Haebe, S., van Bodegom, D., Bird, L., Christie, A. L., Christodoulou, A., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711176 · Cited by 45
Self-citationPeluso, M., Faia, K., Winkler, D. A., Patel, N., Brophy, E. E., White, K., Douglas, M., Stern, H. M., Palombella, V. J., McGovern, K., et al. (2014) · Blood · doi:10.1182/blood.v124.21.328.328 · Cited by 28
Self-citationAlterations of p53 and c-myc in the clonal evolution of malignant lymphoma
Chang, H., Benchimol, S., Minden, M., & Messner, H. (1994) · Blood · doi:10.1182/blood.v83.2.452.452 · Cited by 26
Faia, K., White, K., Proctor, J., Andrade, P. B., Pink, M. M., Rickles, R. J., Grenier, J. M., Boghaert, E. R., Souers, A. J., Leverson, J. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8559 · Cited by 12
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer
Li, C., Xu, X., Wei, S., Jiang, P., Xue, L., & Wang, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001341 · Cited by 360
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Flinn, I. W., Hillmen, P., Montillo, M., Nagy, Z., Illés, Á., Etienne, G., Delgado, J., Kuss, B. J., Tam, C. S., Gasztonyi, Z., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850461 · Cited by 341
Self-citation
Metadata
- Authors
- Horwitz, S. M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J. D., Morrow, S. N., Allen, K., Douglas, M., Stern, H., Sweeney, J., Kelly, P., Kelly, V., Aster, J. C., Weaver, D., Foss, F. M., & Weinstock, D. M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The University of Texas MD Anderson Cancer Center (US)
- Broad Institute (US)
- Infinity Pharmaceuticals (United States) (US)
- Brigham and Women's Hospital (US)
- Verastem (United States) (US)
- Yale Cancer Center (US)
- Corresponding author
- Horwitz, Steven M.
- Koch, Raphael
- Foss, Francine M.
- Weinstock, David M.
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-02-22
- Volume
- 131
- Issue
- 8
- Pages
- 888-898
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC5824337
- OpenAlex
- W2775080684
- Cited by
- 290
- References
- 45
- Citations by year
- 2026: 18 · 2025: 27 · 2024: 32 · 2023: 37 · 2022: 41 · 2021: 45 · 2020: 41 · 2019: 31 · 2018: 18
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- National Human Genome Research Institute (U54HG008097)
- National Cancer Institute (P30CA008748)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- duvelisib, T-cell lymphoma, relapsed/refractory lymphoma, PTCL, patient-derived xenografts, tumor-associated macrophages, macrophage polarization, idelalisib
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Isoquinolines, Male, Middle Aged, Prognosis, Purines, Safety, Skin Neoplasms, Tissue Distribution, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Maximum Tolerated Dose, Class I Phosphatidylinositol 3-Kinases, Class Ib Phosphatidylinositol 3-Kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.